Innovent Biologics (01801.HK) has delivered a surprisingly strong financial performance for the first half of 2026. On August 5, the company reported product sales revenue surging over 55% year-on-year to 8.2 billion yuan, significantly exceeding market expectations of 6.9 billion yuan. This strong growth was particularly evident in the second quarter, where revenue hit 4.3 billion yuan, representing a year-on-year increase of over 60%.

If the momentum continues, with last year's second-half revenue of approximately 6.7 billion yuan growing at a 60% rate, the second-half of 2026 could see revenue near 10.7 billion yuan. Combined with the first-half figure, 2026 total product sales could approach 19 billion yuan, placing the company tantalizingly close to its 2027 target of 20 billion yuan. The market reacted positively, with shares rising 4.15% on the announcement day, pushing the price-to-earnings ratio to a lofty 174 times, reflecting strong expectations for future growth. However, significant challenges lie ahead for the company.

The primary growth driver is entirely domestic

This performance surge is attributed to the company's "oncology and metabolism" dual-engine strategy. Metabolic products have become the new growth pillar, with three key drugs—Mazdutide (for weight loss), Tafolecimab (for cholesterol), and IBI-112 (for a specific condition)—showing significant volume increases. Mazdutide, in particular, is positioned as the core second growth curve after oncology. The domestic GLP-1 drug market is in a golden growth phase, with research suggesting the Chinese GLP-1 market could surpass 71.7 billion yuan by 2029. As the world's first dual GCG/GLP-1 receptor agonist for weight loss, Mazdutide offers differentiated benefits like reducing visceral fat and improving cardiovascular metabolic markers, which has helped it gain rapid market traction. Data from Mi-nei.com showed that in the first quarter of 2026, Mazdutide's online pharmacy sales reached 260 million yuan, making it a new top-selling domestic drug.

However, Innovent Biologics only holds the rights to develop and commercialize Mazdutide in mainland China, Hong Kong, Macau, and Taiwan. Its revenue is entirely dependent on the domestic market, creating a vast gap compared to global industry giants. In contrast, Eli Lilly's (LLY.N) tirzepatide product line generated a combined $27.693 billion in revenue in the first half of 2026, an 88% year-on-year increase, vastly overshadowing Mazdutide's performance. Furthermore, Mazdutide has a significant time-to-market disadvantage. Approved for sale in China in late June 2025, it launched roughly a year after semaglutide and tirzepatide for weight loss, putting it in a catch-up position regarding market share, consumer awareness, and channel development. Nevertheless, the expiration of semaglutide's Chinese patent provides a crucial window for Mazdutide to expand.

To quickly capture market share, Innovent Biologics is accelerating Mazdutide's commercialization on multiple fronts. Online, it is deeply integrated with platforms like JD Health, Ali Health, and Meituan Pharmacy to create a service loop from online consultation to cold-chain delivery. Offline, it is targeting the medical aesthetics market, for example, by releasing an expert guidance document with major hospitals in July to establish a framework for using the drug in aesthetic applications. However, a major issue is that all currently approved GLP-1 drugs in China are prescription-only and lack an indication for aesthetic use. Several regional regulators have issued explicit warnings against using these drugs for weight loss in healthy individuals without metabolic diseases. This aggressive push into the aesthetics market is seen as a symptom of intense competition within the domestic GLP-1 sector. Price wars are already underway, with Novo Nordisk (NVO.N) and Eli Lilly slashing prices. Tirzepatide was added to the National Reimbursement Drug List (NRDL) early this year, with price cuts of over 80% for some dosages, and semaglutide for weight loss followed with similar reductions. Under pressure, Mazdutide began discounting shortly after its launch. For instance, a pack of Mazdutide on Meituan's self-operated pharmacy dropped from 540 yuan to 299 yuan. The outlook is also challenged by a wave of domestic competitors. Hengrui Medicine (600276.SH/01276.HK) has its dual GLP-1/GIP receptor agonist HRS9531 under regulatory review for approval, and numerous generic versions of semaglutide are in late-stage clinical trials, threatening Innovent Biologics' first-mover advantage in the domestic GLP-1 market.

The core cash cow is losing momentum

While the metabolic drug business soars, Innovent Biologics' core oncology business, which established the company's industry standing, is showing signs of slowing growth. The company's primary product, Tyvyt (sintilimab, a PD-1 inhibitor), is facing a growth bottleneck. As the first domestic PD-1 inhibitor included in the NRDL in 2019, Tyvyt achieved explosive sales by leveraging its price advantage. By 2024, its sales exceeded 4 billion yuan, accounting for over 50% of total revenue and helping the company nearly achieve profitability by 2025. However, growth for Tyvyt slowed to just 5% in 2025. This stagnation is attributed to the fading benefits of NRDL inclusion and intensifying competition. With PD-1 products from competitors like Junshi Biosciences (688180.SH/01877.HK), Hengrui, and BeiGene (688235.SH/06160.HK) entering the NRDL with an average 78% price cut, Tyvyt's initial price advantage has diminished. The domestic PD-1 market is now a red ocean, with over 15 approved products, including more than 10 domestic ones. Attempts to expand overseas have been unsuccessful. In March 2022, the US FDA rejected Tyvyt's Biologics License Application, and a subsequent partnership with Eli Lilly ended, forcing the company to abandon its international ambitions for the drug.

The high valuation is under threat from internal and external pressures

Beyond the peak growth in its core business and price wars in its new sector, Innovent Biologics faces internal challenges. Its R&D expenditure in 2025 was 2.624 billion yuan, a rate of 20.1% of sales, a significant decline from 28.4% in 2024. This is lower than peers like BeiGene (40.57%) and Hengrui (27.58%). While some argue the company is focusing its R&D more efficiently, this strategy risks missing breakthrough targets and limiting long-term innovation potential. More concerning is the growing governance divide. At the June 2026 Annual General Meeting, several key resolutions faced significant opposition. The reappointment of Deloitte as auditor saw 22.78% opposition, the authorization to issue new shares faced 36.68% opposition, and the expansion of the share buyback and issuance authority was met with a 48.48% opposition vote, barely passing. These results indicate strong shareholder concerns about auditor independence, management's capital management, and operational authority, rather than the company's overall business performance. This governance tension follows an earlier incident in 2024 where the company was forced to withdraw an overseas subsidiary transaction after facing intense criticism from minority shareholders. Analysts note that in the current environment of valuation re-evaluation for the innovative drug industry, investors have a much lower tolerance for aggressive capital operations and poor governance. The high opposition votes at the AGM represent a check on management's future decisions and create uncertainty for the company's development. While short-term growth is strong, Innovent Biologics must balance commercial gains with long-term innovation and resolve internal governance issues to maintain its high valuation and achieve sustainable growth.